Abbott (NYSE:ABT) shares took a hit this week after Goldman Sachs reduced its rating on the stock to sell, from neutral. The dip also comes on the back of an urgent field safety notice warning on issues with the TactiCath quartz contact force ablation catheter. According to The Street, Goldman Sachs advised investors on June 1 […]
Goldman Sachs gets in on Chinese cardiac valve maker Venus Medtech
Chinese replacement heart valve maker Venus Medtech said today that it won a $37 million commitment from Goldman Sachs (NYSE:GS). Hangzhou-based Venus said it’s also won backing from Qiming Venture Partners, Sequoia Capital China, and Dinova Venture Capital. The company already has a transcatheter aortic valve replacement on the market in the People’s Republic and said a pulmonary […]
Intuitive Surgical to buy back $1B in shares from Goldman Sachs
Biomet puts itself back on public market | Medtech Wall Street news for the week of Mar. 10, 2014
Biomet announces IPO plans
March 7, 2014 by Brad Perriello
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
Biomet announces IPO plans
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
A group of private PE players including the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and TPG acquired Biomet for $11.4 billion in 2007, placing medtech veteran Jeffrey Binder at the helm.
Intuitive Surgical boosts share buyback plan, to repurchase $500M worth from Goldman Sachs
Intuitive Surgical (NSDQ:ISRG) said its board OK’s an additional $779 million worth of share repurchasing, including a planned $500 million buyback from Goldman Sachs.
Volcano shares dive on lowered guidance
Biomet considers spinning out dental | Wall Street Beat
In a growing trend among device makers, Biomet Inc. announced that it’s exploring strategic options to spin out its 3i dental devices division.
The company is just testing the waters and a split isn’t guaranteed, but if completed the move will follow in some notable footsteps.
Goldman to Gorsky: Think small | Wall Street Beat
Johnson & Johnson (NYSE:JNJ) may be worth more in pieces than it is as a whole, at least according to analysts at Goldman Sachs.
Goldman published a research report suggesting that the health care giant split into separate medical device, drug and consumer goods divisions.
Interrad closes $10 million Series C round | Funding Roundup
Interrad Medical Inc. raised $10 million in a Series C round it plans to spend on the development and commercialization of its SecurAcath catheter stabilization device.
The private placement with high-net-worth angels backing the Minneapolis-based med-tech company was brokered by the RBC Wealth Management Group.
"Recently raising 10 million dollars, in a volatile economy, is clearly a testament to the promise of the SecurAcath technology," said Joe Goldberger, Interrad president & CEO, in prepared remarks.
Analysts bearish on C.R. Bard
Analysts at a trio of investment advisory firms downgraded their estimates for C.R. Bard (NYSE:BCR) stock, which hasn’t fared well recently.
